Related Experiment Video
Updated: Jul 8, 2026
04:30
Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a
Weijie Li1,2, Ting Zhou1, Songyuan Luo1
1Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, P. R. China.
Cardiovascular Drugs and Therapy
|July 7, 2026
Summary
This study identified C4B as a potential therapeutic target for calcific aortic valve stenosis (CAVS) by analyzing multi-omic data. C4B is a prioritized candidate for developing new CAVS treatments.
Area of Science:
- Genetics and genomics
- Cardiovascular research
- Drug discovery
Background:
- Calcific aortic valve stenosis (CAVS) lacks effective pharmacotherapies to halt its progression.
- Multi-omic analyses are crucial for identifying novel drug targets in complex diseases like CAVS.
Purpose of the Study:
- To leverage multi-omic data to identify and validate potential drug targets for CAVS.
- To investigate the role of the immune-complement system in CAVS pathogenesis.
Main Methods:
- Integrated druggable genome data with cis-expression quantitative trait loci (eQTLs).
- Performed Mendelian randomization (MR) analysis using two independent genome-wide association study (GWAS) datasets for CAVS.
- Utilized Bayesian colocalization, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes enrichment analyses.
- Verified candidate genes through proteomic (LC-MS/MS) and immunohistochemical (IHC) analyses.
- Conducted phenome-wide association study (PheWAS) and reverse MR analysis to assess pleiotropy and causality.
Main Results:
- Seven druggable genes were significantly associated with CAVS, with C4A and C4B showing robust colocalization.
- LC-MS/MS confirmed upregulation of C4A and C4B proteins in CAVS.
- C4B was identified as a risk factor for CAVS (OR: 1.04, p < 10^-9) and its causal effect was validated by reverse MR.
- IHC showed significantly higher C4B expression in calcific aortic valves, predominantly in interstitial cells.
Conclusions:
- The study provides a genetically anchored therapeutic hypothesis implicating the immune-complement system in CAVS.
- C4B is identified as a prioritized candidate target with significant therapeutic potential for CAVS.
Keywords:
C4BCalcific aortic valve stenosisDrug targetImmunohistochemical analysisMendelian randomizationProteomic analysisMore Related Videos
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:16Calmodulin-dependent Signaling
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...